drugset / Trial / NCT02043132

Tranexamic Acid in Reverse Total Shoulder Arthroplasty

NCT02043132

Phase 2/3 Completed 116 enrolled Corewell Health East
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To the Investigators' knowledge, TXA has not been studied in the setting of reverse total shoulder arthroplasty. We propose a double-blinded, randomized, controlled trial comparing perioperative administration of TXA to placebo in the setting of RTSA. The purpose of this study is to examine the efficacy of TXA in reducing overall blood loss and transfusion rates in patients undergoing reverse total shoulder arthroplasty.

Timeline

Start
2013-09
Primary completion
2015-12
Completion
2016-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule 10 mg/kg Intravenous

Indications